| Event Time: | Monday March 18, 2013 8:00 am to 12:00 pm |
| Topic(s): | Aging and Dementia, Subspecialty in Focus |
| Director(s): | Douglas Galasko MD, Gil Rabinovici MD |
| Description: | As the population ages, the assessment and management of Alzheimer’s disease (AD) and other cognitive disorders will become an increasingly important focus of neurological practice. The past decade has seen significant advances in the development of existing AD biomarkers (e.g. MRI and FDG-PET) and the emergence of new biomarkers that directly detect molecular pathology (amyloid PET and CSF). This program will focus on the translation of AD biomarkers into clinical practice. Clinical applications will be discussed within the framework of new diagnostic guidelines that utilize biomarkers to supplement clinical criteria and increase confidence that AD pathophysiology is present. Participants will receive an update on MRI, PET and CSF-based biomarkers, and case vignettes will be used to illustrate the relative utility of biomarkers in a variety of clinical scenarios. Faculty will provide an update on international efforts to standardize biomarkers across centers, and on ongoing discussions regarding reimbursement for these tests in the U.S. New data on clinical applications of biomarkers will be presented in a poster discussion session and a “data blitz” of oral presentations. The program is intended for clinicians who care for cognitively impaired and geriatric patients, radiologists and nuclear medicine physicians involved in brain imaging interpretation, and researchers focused on AD and associated disorders. This program is offered in partnership with the Society for Nuclear Medicine and Molecular Imaging and the AAN Geriatric Neurology Section. |
| Completion Message: | |
| Program Venue: | IN. Integrated Neuroscience |
| CME Credits: | 4 |
| Core Competencies: | Patient Care, Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Practice-Based Learning and Improvement, Systems-Based Practice |
| Start/End Time | Title | Faculty |
|---|---|---|
| 8:00 AM - 8:10 AM | Introduction: The Emerging Role of Biomarkers in Alzheimer's Disease Criteria and Clinical Care | Gil Rabinovici MD |
| 8:10 AM - 8:40 AM | Medial Temporal and Alzheimer's Disease Pattern Atrophy Measures in Clinical Practice | Giovanni Frisoni MD |
| 8:40 AM - 9:10 AM | Glucose Metabolism and the Behavioral Phenotype of Alzheimer's Disease | William Jagust MD |
| 9:10 AM - 9:40 AM | CSF Biomarkers: A Helpful Tool in the Diagnosis of Alzheimer's Disease | Douglas Galasko MD |
| 9:40 AM - 10:10 AM | Amyloid Imaging: Diagnostic Paradigm Shift or Limited Clinical Role? | Gil Rabinovici MD |
| 10:10 AM - 10:30 AM | Discussion: Utilizing Biomarkers in the Clinic - Practical Considerations | Faculty |
| 10:30 AM - 11:30 AM | Poster Rounds | None |
| 11:30 AM - 12:00 PM | Data Blitz Presentations | None |
| Poster Session | ||||
|---|---|---|---|---|
| Start Time | Pub. | Title | Presenter | |
| 10:30 AM | 001 | Acceleration of Brain Injury Biomarker Abnormalities in Cognitively Normal Elderly with ?-Amyloidosis | David Knopman, MD, FAAN | |
| 10:30 AM | 002 | Increased CSF Neurofilament Light Chain Reflects Disease Severity in Frontotemporal Degeneration | Carole Scherling, PhD | |
| 10:30 AM | 003 | Novel CSF Tau Assays Demonstrate Different Abnormalities in Severity-Matched Alzheimer's Disease and Progressive Supranuclear Palsy | Dana Wagshal, PhD | |
| 10:30 AM | 004 | Presence of Brain Amyloidosis Can Be Ascertained from Cognitive, Imaging and Peripheral Blood Protein Measures | Liana Apostolova, MD | |
| 10:30 AM | 005 | CSF PKR Is a Diagnostic and Prognostic Marker in Alzheimer's Disease | Jacques Hugon, MD PhD | |
| 10:30 AM | 006 | Lack of Substantial Progression of Cognitive Deficits in Patients with Negative Amyloid Imaging: Implications for Clinical Trials | Andrew Siderowf, MD | |
| 10:30 AM | 007 | Positive PIB-PET Is Associated with High Post-Mortem Amyloid Burden in Dementia Patients | Manja Lehmann, PhD | |
| 10:30 AM | 008 | DaTscan Findings in Patients with Mild Cognitive Impairment, Alzheimer's Disease and Dementia with Lewy Bodies | Bradley Boeve, MD | |
| 10:30 AM | 009 | A Multi-Site Validation of Human A?42 and Human Total Tau Assays for Use in Human CSF | Pankaj Oberoi | |
| 10:30 AM | 010 | Quantitative MRI Biomarkers of Neurodegenerative Diseases: Moving from Scientific Insights toward Clinical Practice | Bradford Dickerson, MD | |
| Platform Session | ||||
| Start Time | Pub. | Title | Presenter | |
| 11:30 AM | 001 | Comparison of [18F]Flutemetamol PET Image Interpretation with Clinical Diagnosis of Alzheimer's Disease: Neuritic Plaque Density Standard Based on Consortium To Establish a Registry for Alzheimer's Disease Criteria | Stephen Salloway, MD, MS, FAAN | |
| 11:35 AM | 002 | Neuropathologic Basis of White Matter Hyperintensity Accumulation | Deniz Erten-Lyons, MD | |
| 11:40 AM | 003 | Predictive Value of CSF Biomarkers for Alzheimer's Disease in an Italian Cohort of Patients with Mild Cognitive Impairment | Elisa Rubino, MD | |
| 11:45 AM | 004 | Amyloid Deposition and Hippocampal Volume as Predictors of Incident Dementia in Non-Demented Very Elderly Subjects | Oscar Lopez, MD | |
| 11:50 AM | 005 | Validation and Comparison of NIA-AA and IWG Diagnostic Criteria for Alzheimer's Disease in MCI Patients Coming from Three European Memory Clinics | Giovanni Frisoni, MD | |
| Half-Day Course (9:00 AM-1:00 PM) | ||
|---|---|---|
| 2HC.001 | Clues to Synuclein Spread in Parkinson's Disease | Kathleen Shannon MD |
| 2HC.005 | Leukodystrophies | Adeline Vanderver MD |
| Integrated Neuroscience (8:00 AM-12:00 PM) | ||
|---|---|---|
| Half-Day Course (9:00 AM-1:00 PM) | ||
| 3HC.001 | The Visual and Ocular Motor Systems in Neurodegenerative and Genetic Disease | David Zee MD, FAAN |
| 3HC.008 | Amyloid Imaging: Are Neurologists Ready for the Paradigm Shift? | Norman Foster MD, FAAN |
| Scientific Poster Session (2:00 PM-6:30 PM) | ||
| 3PS.001 | Poster Session 1 | |
| Scientific Platform Session (1:00 PM-2:45 PM) | ||
|---|---|---|
| 4SS.004 | Amyloid Imaging in the Prediction of and Diagnosis of Alzheimer's Disease | |
| Integrated Neuroscience (1:00 PM-5:00 PM) | ||
| 4IN.001 | Global Impact of Non-communicable Neurological Diseases | Massimo Pandolfo MD, Jerome Chin MD, PhD, MPH |
| Scientific Poster Session (2:00 PM-6:30 PM) | ||
| 4PS.003 | Poster Session 3 | |
| Scientific Poster Session (7:30 AM-12:00 PM) | ||
|---|---|---|
| 5PS.004 | Poster Session 4 | |
| Scientific Platform Session (2:00 PM-3:45 PM) | ||
| 5SS.024 | Aging and Dementia: Epidemiology and Clinical Science | |
| Scientific Poster Session (2:00 PM-7:00 PM) | ||
| 5PS.005 | Poster Session 5 | |
| Poster Discussions (2:00 PM-7:00 PM) | ||
| 5PD.005 | Aging and Dementia: Genetics Poster Discussion Session | |
| Scientific Platform Session (4:00 PM-5:30 PM) | ||
| 5SS.034 | Aging and Dementia: Genetics and Biochemical Markers | |
| Highlights in the Field/Section Topic Controversies (6:30 PM-7:30 PM) | ||
| 5SH.004 | Geriatric Neurology Highlights in the Field | |
| Scientific Poster Session (7:30 AM-12:00 PM) | ||
|---|---|---|
| 6PS.006 | Poster Session 6 | |
| Scientific Platform Session (12:00 PM-1:45 PM) | ||
| 6SS.044 | Aging and Dementia: Imaging and Neuropathology | |
| Integrated Neuroscience (12:00 PM-4:00 PM) | ||
| 6IN.001 | Toward a Dimorphic Neurology: Implications for Men's and Women's Health | Walter Rocca MD, MPH, Mark Mehler MD, FAAN |
| Scientific Poster Session (2:00 PM-7:00 PM) | ||
| 6PS.007 | Poster Session 7 | |
| Integrated Neuroscience (8:00 AM-12:00 PM) | ||
|---|---|---|
| 7IN.001 | Inflammation in Epilepsy | Jacqueline French MD, FAAN, Tallie Baram MD, PhD |
| Half-Day Course (8:00 AM-12:00 PM) | ||
| 7HC.001 | Neurorehabilitation Enhancement Techniques | Randolph Marshall MD, FAAN |
| Integrated Neuroscience (1:00 PM-5:00 PM) | ||
| 7IN.003 | Brain Stimulation: Clinical and Neuroscience Implications | Anjan Chatterjee MD, FAAN, H. Coslett MD, FAAN |
| Half-Day Course (1:00 PM-5:00 PM) | ||
| 7HC.010 | Epilepsy Co-morbidities | William Theodore MD, FAAN |